P1410: EFFICACY OBSERVATION OF A SECOND INFUSION OF BCMA-CAR-T CELLS IN PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA

• DOI: 10.1097/01.hs9.0000972528.22796.66
• Publication Date: 2023-08-08T16:29:04Z
• Authors: Yi Wang; Ben Niu; Limin Hou; Ding Zhang; Qiuying Gao; Hui Wang; Ying Gao; Yudi Miao; Xinhui Zhai; Ying Guo; Weihua Zhang; Xingli Ru; Yi Zhang
• Keywords: Refractory (planetary science); Hematology; Clinical efficacy

Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Chimeric antigen receptor (CAR) T-cell therapy has exhibited remarkable clinical efficacy in the treatment of relapsed/refractory multiple myeloma (R/RMM), BCMA-targeted CAR-T cell for R/RMM can achieve an effective rate more than 90%, with 70% patients obtaining complete response (CR).However, even among CR, relapse progression disease may still occur, currently there are few reports on effectiveness a second infusion same target after disease. Aims: To preliminarily analyze adverse reactions receiving R/RMM. Methods: The reactions, factors affecting (including third) Department Hematology Shaanxi Provincial People’s Hospital performed from March 2021 to January 2022 were retrospectively analyzed, cut-off time observation period was at death patient or February 26, 2023. Results: A total 24 [males vs. females (13 11), median age 57 years (44 –70 years)] who received BCMA-CAT-T included this study, which 70.8% (17/24) type IgG, 16.7% (4/24) IgD, 4.2%(1/24) light-chain, 8.3% (2/24) IgA. For first 45.8% (11/24) 12 months 54.2% (13/24) less months. converted murine human CAR-T, humanized infusion. 83.3% (20/24) only one before, twice past. After BCMA-CAR-T infusion, 58.3 % (14/24) had cytokine release syndrome (CRS), 50% (12/24) grade 1 CRS, 2 4.2% (1/24) central nervous system reaction. 5 (range: 1-18 months). overall (ORR) 83.3 (20/24), which，41.6% achieved (CR), very good partial (VGPR), 25% (6/24) (PR). died during period, survival 51.8 %. Summary/Conclusion: afterwards showed progressive relapse, could receive therapy. Keywords: Multiple